LAWRENCE, Mass., Aug. 8, 2016 NxStage Medical,
Inc. (Nasdaq: NXTM), a leading manufacturer of
dialysis products, today announced the release of new enhanced
priming features, the first of many upcoming capabilities of its
next generation hemodialysis system. The features are
designed to be used for home treatments with current and next
generations of the NxStage System One.
"We're excited to be providing patients and customers with
access to these new features that deliver on our promise to reduce
the amount of time and effort involved for patients to set up their
System One for treatment," said Joseph E.
Turk, president of NxStage. "These features improve the
overall ease of use of the System One and are the first of many new
features and capabilities to come to support our NxGen system."
The new priming features are immediately available in
the United States. For more
information, please visit www.nxstage.com.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home nocturnal
hemodialysis. Its simplicity and revolutionary size (just over a
foot tall) are intended to allow convenient use in patients' homes
and give patients the freedom to travel with their therapy. When
combined with the NxStage PureFlow SL Dialysis Preparation System,
patients are able to further simplify, using ordinary tap water to
create dialysis fluid on demand. Unlike conventional hemodialysis
systems, the System One requires no special infrastructure to
operate. Under the guidance of their physician, patients can use
the NxStage System One, with their trained partners, where, how and
when it best meets their needs, including while they are sleeping -
at home or on vacation and at a medically appropriate treatment
frequency. In addition, NxStage's Nx2me Connected Health platform
collects important NxStage System One and patient information for
flexible viewing, monitoring and reporting that may improve patient
management and simplify alternative site care. The System One is
also used to provide a range of flexible therapy options in more
traditional care settings such as hospitals and dialysis centers.
Its safety and efficacy have been demonstrated by experience with
more than 13 million treatments with thousands of patients around
the world. http://www.nxstage.com/.
About NxStage
NxStage Medical, Inc. (Nasdaq: NXTM) is
a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
end-stage renal disease (ESRD) and acute kidney failure. NxStage
has also established a small number of dialysis clinics committed
to the development of innovative care delivery models for patients
with ESRD. For more information on NxStage and its products and
services, please visit the Company's website at
http://www.nxstage.com and www.nxstagekidneycare.com.
Forward Looking Statements
This release contains
forward-looking statements concerning our business, operations and
financial condition. All statements contained in this release that
are not clearly historical in nature are forward-looking, and the
words "anticipate," "believe," "expect," "estimate," "plan," and
similar expressions are generally intended to identify
forward-looking statements. Examples of these forward-looking
statements include statements as to the anticipated release of
future NxGen product features and capabilities. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond NxStage's control, which
may cause actual results, performance, or achievements to differ
materially from anticipated results, performance or achievements,
including market acceptance and demand for NxStage's products
domestically and internationally, regulatory approvals,
unanticipated difficulties in achieving development objectives or
timelines, and certain other factors that may affect future
operating results and which are detailed in NxStage's filings with
the Securities and Exchange Commission, including the Quarterly
Report on Form 10-Q for the quarter ended June 30, 2016.
Media contact:
Kristen K.
Sheppard, Esq.
ksheppard@nxstage.com
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-launches-first-of-many-nxgen-features-and-capabilities-300309866.html
SOURCE NxStage Medical, Inc.